Premium
Long‐term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: A retrospective study
Author(s) -
Querol Luis,
RojasGarcia Ricard,
Casasnovas Carlos,
Sedano Maria Jose,
MuñozBlanco Jose Luis,
Alberti Maria Antonia,
Paradas Carmen,
Sevilla Teresa,
Pardo Julio,
Capablo Jose Luis,
Sivera Rafael,
Guerrero Antonio,
GutierrezRivas Eduardo,
Illa Isabel
Publication year - 2013
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.23843
Subject(s) - chronic inflammatory demyelinating polyneuropathy , medicine , retrospective cohort study , polyneuropathy , intravenous immunoglobulins , surgery , pediatrics , antibody , immunology
: The objective of this retrospective study was to describe the short‐ and long‐term patterns of IVIg use, safety, and response to treatment in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Methods : Response to therapy was defined as an improvement of ≥1 point on the modified Rankin score at short‐ and mid‐term visits. Patient status at long term was classified as remission, stability, or non‐responder. Results : Eighty‐six patients were included; 60.5% responded at short term and 54.6% at mid‐term. At long term, 25.6% of patients were in remission, 65.1% were stable, and 9.3% were non‐responders. The only variable associated with remission was a better response during the first 6 months of follow‐up. Conclusions : A significant percentage of patients did not require any additional drugs in the long term. This suggests that treatment effect or disease outcome may be stable over time, and treatment regimens should therefore be individualized to avoid overtreatment. Muscle Nerve 48 : 870–876, 2013